Key result
Dimethyl fumarate reduces MS black hole T1 relaxation times ~6%, correlating with clinical improvement.
Why the study?
Quantitative MR imaging parameters may help evaluate disease progression and increase correlation with clinical disability in multiple sclerosis.
Does T1 relaxation time correlate with clinical improvement in patients with relapsing-remitting MS treated with dimethyl fumarate?
Cohort (n=17)
No
Does T1 relaxation time correlate with clinical improvement in patients with relapsing-remitting MS treated with dimethyl fumarate?
Absolute Event Rate: 1369.4% vs 1460.2%
p-value: p=<0.001
Decreasing T1 relaxation times in black holes on MRI are associated with clinical improvement in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
T1 shortening in black holes may mark tissue recovery on DMF; hypothesis-generating for quantitative T1 mapping as biomarker, needing larger prospective validation.
BACKGROUND AND PURPOSE: Quantitative MR imaging parameters help to evaluate disease progression in multiple sclerosis and increase correlation with clinical disability. We therefore hypothesized that T1 values might be a marker for ongoing tissue damage or even remyelination and may help increase clinical correlation. MATERIALS AND METHODS: MR imaging was performed in 17 patients with relapsing-remitting MS at baseline and after 12 months of starting immunotherapy with dimethyl fumarate. On baseline images, lesion segmentation was performed for normal-appearing white matter, T2 hyperintense (FLAIR lesions), T1 hypointense (black holes), and contrast-enhancing lesions, and T1 relaxation times were obtained at baseline and after 12 months. Changes in clinical status were assessed by using the Expanded Disability Status Scale and Symbol Digit Modalities Test at both dates (Expanded Disability Status Scale-difference/Symbol Digit Modalities Test-diff). RESULTS: The highest T1 relaxation time at baseline was measured in black holes (1460.2 ± 209.46 ms) followed by FLAIR lesions (1400.38 ± 189.1 ms), pure FLAIR lesions (1327.5 ± 210.04 ms), contrast-enhancing lesions (1205.59 ± 199.95 ms), and normal-appearing white matter (851.34 ± 30.61 ms). After 12 months, T1 values had decreased significantly in black holes (1369.4 ± 267.81 ms), contrast-enhancing lesions (1079.57 ± 183.36 ms) (both P < .001), and normal-appearing white matter (841.98 ± 36.1 ms, P = .006). With the Jonckheere-Terpstra Test, better clinical scores were associated with decreasing T1 relaxation times in black holes (P < .05). CONCLUSIONS: T1 relaxation time is a useful quantitative MR imaging technique, which helps detect changes in MS lesions with time. We assume that these changes are associated with the degree of myelination within the lesions themselves and are pronounced in black holes. Additionally, decreasing T1 values in black holes were associated with clinical improvement.
No takes yet. Share an insight, caveat, or question.
Thaler et al. (2016) conducted a cohort in Relapsing-remitting multiple sclerosis (n=17). Dimethyl fumarate vs. Baseline was evaluated on T1 relaxation time in black holes (ms) (p=<0.001). Over 12 months of dimethyl fumarate treatment, T1 relaxation times in multiple sclerosis black holes significantly decreased from 1460.2 ms to 1369.4 ms, which was associated with clinical improvement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: